Human papillomavirus genotype distribution in genital warts among women in Harare-Zimbabwe.

This study aimed to determine the prevalence of HPV genotypes in genital warts among women in Harare, Zimbabwe. Women aged 18-45 years attending gynaecology and genitourinary clinics with a clinical diagnosis of genital-warts were recruited. HPV-DNA was extracted from tissue biopsies. HPV-DNA testing and typing was done by Southern Dot Blot Hybridisation. A hundred samples from 100 women were analysed. Median age of participants was 30.3 years (range 18-45 years). Seventy-eight percent of participants were HIV infected. HPV prevalence was 98%. Low risk genotypes predominated at 86% prevalence. The most prevalent genotypes were 11 (47%), 6 (42%) and 16 (14%). This is the first study on HPV genotype distribution among women with genital warts in Zimbabwe. The high prevalence of HR-HPV 16 in clinically benign lesions shows that warts should have histological analysis to exclude pre-malignancy and malignancy.Impact statementWhat is already known on this subject? Genital warts (GWs), also known as condylomata acuminata (EAC), are a clinical manifestation of persistent infection with 'low risk' or non-oncogenic HPV genotypes. HPV 6 and 11 are examples of low risk genotypes, and both are associated with 90% of GWs. Data on HPV genotypes causing genital warts in the population under study are scarce.What do the results of this study add? A high prevalence (98%) of HPV DNA in genital warts, confirms that the biopsied lesions were HPV related. Over and above the hi...
Source: Journal of Obstetrics and Gynaecology - Category: OBGYN Tags: J Obstet Gynaecol Source Type: research

Related Links:

Adults up to age 45 can now be vaccinated against human papillomavirus (HPV), reducing their chances of getting cervical, oral and other cancers. The Food and Drug Administration (FDA) announced Friday that Gardasil 9, a vaccine that works against nine different types of HPV, is now approved for both men and women between the ages of 27 and 45. Previously, it was approved only for those between the ages of nine and 26, and recommended for all children at age 11 or 12. “Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” Dr. Peter M...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime onetime public health Source Type: news
More teenagers than ever before are getting vaccinated against human papillomavirus (HPV), according to new data from the Centers for Disease Control and Prevention (CDC). Federal guidelines now say that all children should start two-dose HPV vaccination at age 11 or 12 to protect against HPV-associated cervical, vaginal, penile, anal and throat cancers. Despite that recommendation, however, HPV vaccination rates have traditionally lagged far below their targets. That’s still true — but the new report does suggest that rates are rising. Between 2016 and 2017, the CDC says, the percentage of teenagers who report...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized healthytime onetime public health Source Type: news
Background Human papillomavirus (HPV) is the most common sexually transmitted infection, with at least half of sexually active people contracting the virus—a leading etiology for genital warts and anal, cervical, laryngeal, penile, vaginal, and vulvar cancers. Research suggests HPV is higher among U.S. military personnel than in U.S. civilian populations and can result in significant morbidity or complications and limit U.S. military’s duties or deployable status. Objectives The aim of the study was to identify determinants of HPV vaccination among U.S. Navy personnel. Methods Participants (N = 233) rec...
Source: Nursing Research - Category: Nursing Tags: Brief Report Source Type: research
CONCLUSIONS: Most women with vulvar carcinoma are older than 70 years. VIN3 and VAIN3 are associated with HPV infection and the most prevalent type is HPV16. Almost half the vaginal cancers are associated with metastases from other organs and almost half of VAIN3 is associated with past cervical dysplasia or carcinoma. PMID: 27430086 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: Journals (General) Tags: Isr Med Assoc J Source Type: research
Human papillomavirus (HPV) is the most common sexually transmitted infection. It affects 80% of the population, with the initial infection usually occurring between 15 and 24 years of age. Persistent infection with high-risk oncogenic HPV genotypes, primarily types 16 and 18, is the cause of almost all cervical cancers.1 HPV is also thought to cause about 95% of anal cancers, 75% of oropharyngeal cancers, 75% of vaginal cancers, 70% of vulvar cancers, and 60% of penile cancers.2 Low-risk or non-oncogenic genotypes (eg, types 6 and 11) cause anogenital warts, low-grade cervical disease, and recurrent respiratory papillomatosis.
Source: LANCET - Category: Journals (General) Authors: Tags: Comment Source Type: research
Human papillomavirus (HPV) is a DNA virus that causes a variety of conditions including common warts, condyloma acuminata (anogenital warts), and multiple malignancies involving the squamous epithelium. HPV is a unique oncogenic infectious agent that causes cervical cancer, the second most common cancer in women worldwide.1 In addition to cervical cancer, HPV is responsible for a large proportion of penile cancer, vaginal/vulvar cancer, anal cancer, and oropharyngeal cancer. The disease burden is significant with HPV-associated cancers totaling 35,000 new diagnoses in 2009, 3% of all US cancer diagnoses.
Source: Disease a Month - Category: Infectious Diseases Authors: Source Type: research
While currently recommended for both boys and girls, the HPV vaccine was initially marketed -- and is still thought of -- as a way to protect young women and girls from cervical, vaginal and vulvar cancer. Boys, it's been commonly thought, should be vaccinated primarily to benefit herd immunity and any future female partners. But a new analysis from researchers at the Princess Margaret Cancer Center in Toronto, Canada, points out that boys who get the vaccine receive important protection as well, not only against genital warts, but against HPV strains that cause oropharyngeal (mouth and throat) cancer. "We believe t...
Source: Science - The Huffington Post - Category: Science Source Type: news
Conditions:   Cervical Cancer;   Vulvar Cancer;   Vaginal Cancer;   Genital Warts;   Human Papillomavirus InfectionInterventions:   Biological: Comparator: GARDASIL;   Biological: Experimental: V503Sponsor:   Merck Sharp & Dohme Corp.Active, not recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cervical Cancer;   Vulvar Cancer;   Vaginal Cancer;   Genital Warts;   Human Papillomavirus InfectionInterventions:   Biological: Comparator: V505 formulation 1;   Drug: Comparator: V505 formulation 2;   Drug: Comparator: V505 formulation 2;   Biological: Comparator: V505 formulation 3;   Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant;   Biological: Comparator: Placebo (unspecified)Sponso...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Genital Warts | HPV Testing | Human Papillomavirus (HPV) | OBGYN | Study | Vaccines | Vulvar Biopsy | Vulvar Cancer | Warts | Women | Zimbabwe Health